Program
Alprazolam
Also written as “Alprazolam Extended-Release 3 mg Tablets”, “Staccato alprazolam” and “alprazolam XR”.
Its studies are mostly in Anxiety Disorders · Panic Disorder · Seizures · Epilepsy · Asthma, led by 6 companies.
Drug pageAlprazolam: every studyMany companies study it; this page follows only the 26 they lead. All 62 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 120 open or running | phase 4since Mar 5, 2008 | Oct 26, 2005 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| GlaxoSmithKline | 30 open or running | phase 1since Nov 28, 2012 | Nov 28, 2012 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Jun 2, 2009 | Jun 2, 2009 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 20 open or running | phase 1since Apr 8, 2009 | Apr 8, 2009 | none ahead |
| Nova Pneumaits history only | 10 open or running | phase 1since Jan 17, 2008 | Jan 17, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 28, 2012First study: phase 1 study in Anxiety DisordersFirst studyNCT01853956 · 28 enrolled
- Dec 6, 20122 phase 1 studies in Anxiety DisordersNCT01745575, NCT01745562
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Midazolamrule | Eli Lilly | phase 4 | 97 |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 14 |
| Diazepamrule | Acorda Therapeutics | phase 3 | 9 |
Studies
All 3 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01745575Anxiety Disorders | 1 | Completed | Apr 5, 2010 | 26 |
| NCT01745562Anxiety Disorders | 1 | Completed | Dec 17, 2010 | 28 |
| NCT01853956Anxiety Disorders | 1 | Completed | Dec 10, 2010 | 28 |
How it is read
Names in the registry
- “Alprazolam”, 10 entries
- “Alprazolam Extended-Release 3 mg Tablets”, 4 entries
- “Staccato alprazolam”, 3 entries
- “alprazolam XR”, 3 entries
- “Staccato Alprazolam”, 2 entries
Conditions, from the studies’ own filings
- Anxiety Disorders, 5 studies
- Panic Disorder, 3 studies
- Seizures, 2 studies
- Epilepsy, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.